Eli Lilly Broadens Metabolic Reach as UK Launch Coincides With Pipeline Expansion

Eli Lilly launches Foundayo in UK, reports positive Zepbound-Taltz combo data, and JPMorgan raises 2027 estimates despite soft share price.

Eli Lilly’s push into new markets and new therapeutic combinations is gathering pace, with the company’s oral obesity treatment Foundayo now available to private patients in the United Kingdom — the first European country to offer the drug through prescription channels. The UK’s medicines regulator cleared Foundayo on 10 August, though access through the state-funded NHS remains contingent on a separate review process.

The British rollout lands at a moment when the Indianapolis-based drugmaker is recalibrating its pricing strategy across the entire metabolic franchise. Reuters reported that Lilly committed back in November to cap monthly costs for Medicare beneficiaries at $50 for both Zepbound and the orforglipron product marketed as Foundayo, supplementing out-of-pocket discounts available through its LillyDirect platform. On that platform, Zepbound’s multi-dose pen starts at $299 per month, while Foundayo comes in at $149. The TrumpRx channel adds Emgality at $299 per pen and Trulicity at $389 monthly, according to Reuters.

Clinical Momentum Extends Beyond Weight Management

The UK market entry forms part of a broader wave of regulatory and clinical advances. The FDA recently widened Mounjaro’s approval to include cardiovascular risk reduction in high-risk patients with type 2 diabetes. Meanwhile, Lilly released one-year Phase 3b data from the TOGETHER-PsO and TOGETHER-PsA studies, which evaluated the combination of Zepbound and the psoriasis therapy Taltz in adults with both psoriatic disease and excess weight. After 52 weeks, the regimen held disease activity steady or improved it relative to Taltz alone, with no new safety signals reported.

These findings underscore a deliberate strategy of positioning tirzepatide — the active ingredient in Zepbound and Mounjaro — well beyond its original diabetes and obesity indications. The company is also investigating the molecule in two Phase 3 trials as a disease-modifying treatment for type 1 diabetes, according to media reports citing an analysis. Pairing the drug with an established immunology product like Taltz opens the door to inflammatory skin conditions in overweight patients, a population often underserved by any single drug class.

Lilly’s immunology ambitions extend to dealmaking as well. The recently agreed acquisition of Merida Biosciences, valued at up to $2.875 billion, brings with it MER511, a candidate for Graves’ disease and endocrine orbitopathy. Taken together with the latest study results, the picture emerging is one of a company deliberately intertwining metabolic and immune therapies rather than advancing them along separate tracks.

The FDA has also tightened its stance on unauthorized peptide products sold by online vendors, a move that followed a legal initiative by Lilly concerning the active ingredient retatrutide, as reported by Inside Health Policy. The company is thus defending its market turf against copycat products while simultaneously rolling out its own portfolio across multiple countries and price points.

Analyst Optimism Persists Despite Soft Share Price

Wall Street remains constructive on the growth trajectory. On 3 September, JPMorgan raised its 2027 revenue estimate by 0.7% to $105.67 billion and lifted its earnings-per-share target by 1.1% to $50.99. The bank reaffirmed its $1,400 price objective with an Overweight rating, projecting combined sales from Zepbound, Mounjaro and Foundayo of $62 billion this year, $78 billion by 2027 and north of $100 billion by 2030.

The share price, however, tells a more subdued story. The stock closed Friday at €986.00, down 1.1% on the day and 4.0% lower over the past month. That leaves the equity roughly 11% beneath its 52-week high of €1,108.20, reached in mid-August. The relative strength index of 39.8 points to cautious sentiment without signaling an oversold condition. In euro terms, the shares currently trade at €989.60, about 4.3% below their 50-day moving average of €1,033.56 — a pattern consistent with short-term consolidation following the August peak.

Investors will have opportunities to reassess the risk-reward calculus shortly. The regular quarterly dividend of $1.73 per share is scheduled for payment on 10 September, and Ilya Yuffa, President of Lilly USA, is set to appear at the Morgan Stanley 24th Annual Global Healthcare Conference on 14 September, where pipeline details, pricing strategy and commercialization plans are likely to feature prominently. For now, the tension between a steady drumbeat of fundamental progress and a hesitant tape leaves the stock in a holding pattern — one that fresh catalysts could break in either direction.